U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07131202) titled 'A Study of FL115 Injection in Combination With a PD-1 Antibody in Advanced Solid Tumors' on July 21.
Brief Summary: This is an open-label, multicenter, Phase Ib/II clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of FL115 injection in combination with the anti-PD-1 monoclonal antibody, in participants with advanced solid tumors. All enrolled participants will receive FL115 and Sintilimab via intravenous (IV) infusion. Treatment will continue until disease progression (excluding pseudoprogression), unacceptable toxicity, or other protocol-specified criteria for s...